/
/
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients image
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients
Posted Apr 12, 2018

Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is obtaining FDA fast-track status for myeloma patients who have received three prior lines of therapy. Those three lines must have included five different drug classes:

  1. Chemotherapy like melphalan or cyclophosphamide
  2. A proteasome inhibitor like bortezomib or carfilzomib
  3. An immunomodulator like lenalidomide or pomalidomide
  4. A steroid like dexamethasone
  5. Daratumumab

 

The FDA’s statement is based on results from Karyopharm’s Phase 2b STORM study. According to Sharon Shacham, MD, PhD, Founder, President and Chief Scientific Officer of Karyopharm:

 

“The designation of Fast Track for selinexor represents important recognition by the FDA of the potential of this anti-cancer agent to address the significant unmet need in the treatment of patients with penta-refractory myeloma that has continued to progress despite available therapies. We are fully committed to working closely with the FDA as we continue development of this potential new, orally-administered treatment for patients who currently have no other treatment options of proven benefit.”

To find all selinexor clinical trials, click below:

Selinexor Clinical Trials

To learn how selinexor works, watch the video below with Dr. David Siegel of the John Theurer Cancer Center.


The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811